Massachusetts Financial Services Co. MA Increases Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• Massachusetts Financial Services Co. MA boosted its stake in Bristol Myers Squibb by 835.7% in Q4, buying an additional 685,961 shares to hold 768,040 shares valued at about $41.4 million.
• EVP David V. Elkins sold 30,000 shares at an average of $61.67 on April 1, reducing his holding by 15.85% to 159,248 shares; insiders own roughly 0.05% of BMY.
• Bristol Myers Squibb declared a quarterly dividend of $0.63 per share (annualized $2.52), a 4.3% yield, with an ex-dividend date of April 2 and payment on May 1.

Massachusetts Financial Services Co. MA boosted its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 835.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 768,040 shares of the biopharmaceutical company's stock after buying an additional 685,961 shares during the quarter. Massachusetts Financial Services Co. MA's holdings in Bristol Myers Squibb were worth $41,428,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of BMY. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb in the 2nd quarter valued at $25,000. Harbor Capital Advisors Inc. lifted its stake in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 313 shares during the last quarter. KERR FINANCIAL PLANNING Corp purchased a new position in Bristol Myers Squibb in the third quarter valued at about $35,000. JPL Wealth Management LLC purchased a new position in Bristol Myers Squibb in the third quarter valued at about $36,000. Finally, Beacon Financial Strategies CORP bought a new position in Bristol Myers Squibb in the fourth quarter worth about $38,000. Institutional investors own 76.41% of the company's stock.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.05% of the stock is currently owned by insiders.

Bristol Myers Squibb Price Performance

Shares of BMY stock opened at $58.09 on Wednesday. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm has a market capitalization of $118.60 billion, a price-to-earnings ratio of 16.84, a PEG ratio of 0.17 and a beta of 0.27. The stock's 50-day simple moving average is $59.86 and its 200-day simple moving average is $53.44.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts' consensus estimates of $1.65 by ($0.39). The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm's revenue for the quarter was up 1.3% on a year-over-year basis. During the same quarter last year, the business earned $1.67 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. Bristol Myers Squibb's payout ratio is 73.04%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. UBS Group restated a "buy" rating and issued a $70.00 price target on shares of Bristol Myers Squibb in a report on Friday, March 6th. Wells Fargo & Company reissued an "outperform" rating and set a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Bank of America lowered their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a research note on Thursday, April 9th. Royal Bank Of Canada began coverage on shares of Bristol Myers Squibb in a report on Tuesday, February 24th. They issued a "sector perform" rating and a $60.00 price target on the stock. Finally, Guggenheim reaffirmed a "buy" rating and set a $72.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $61.71.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.